INTRODUCTION
Medical Cannabis Supporting Patients in the UK
Medical cannabis has evolved from a controversial topic into a growing therapeutic option in the UK. Since its legalisation for medical use in 2018, thousands of patients have accessed cannabis-based products to manage chronic conditions where conventional treatments have failed. Despite promising results, access remains limited—especially through the NHS—fueling debates around healthcare equity, regulation, and research.
This guide outlines everything you need to know about how medical cannabis supports patients in the UK in 2025, including its legal framework, who qualifies, how to access it, benefits, costs, and the challenges patients still face.
—
LEGAL FRAMEWORK AND REGULATION
WHEN DID MEDICAL CANNABIS BECOME LEGAL?
In November 2018, the UK government rescheduled cannabis-based medicinal products (CBMPs) under the Misuse of Drugs Regulations 2001, allowing doctors on the General Medical Council (GMC) Specialist Register to prescribe them. Cannabis was previously a Schedule 1 drug, meaning it had no recognised medical use. With the law change, certain forms of cannabis were moved to Schedule 2, permitting medical use under strict controls.
WHAT DOES THE LAW ALLOW IN 2025?
As of 2025:
Only specialist consultants can initiate a medical cannabis prescription.
Cannabis remains illegal for recreational use.
GPs can participate in shared care after a specialist initiates treatment.
Prescriptions can be issued for both licensed and unlicensed products under UK law.
—
WHO CAN PRESCRIBE MEDICAL CANNABIS?
SPECIALIST CONSULTANTS
Only a consultant listed on the GMC Specialist Register—such as neurologists, pain specialists, oncologists, and psychiatrists—can prescribe CBMPs legally. These prescriptions must be made on a case-by-case basis when other treatment options have been exhausted.
ROLE OF PRIVATE CLINICS
Because NHS access remains restricted, most prescriptions occur through private medical cannabis clinics, which employ certified specialists. Clinics like Sapphire Medical, Mamedica, Lyphe Group, and Cantourage have become leading providers, serving an estimated 45,000 patients by early 2025.
—
WHO QUALIFIES FOR MEDICAL CANNABIS?
NHS-ELIGIBLE CONDITIONS
On the NHS, medical cannabis is currently prescribed in rare cases for:
Severe treatment-resistant epilepsy (e.g. Lennox-Gastaut, Dravet syndrome)
Multiple Sclerosis (MS)-related muscle stiffness/spasticity
Chemotherapy-induced nausea and vomiting
WIDER ELIGIBILITY IN PRIVATE CARE
In private clinics, cannabis is prescribed for a broader range of conditions, including:
Chronic pain (arthritis, fibromyalgia, endometriosis)
Anxiety, depression, PTSD
Migraines
Sleep disorders (e.g. insomnia)
Autism Spectrum Disorder
ADHD
Irritable Bowel Syndrome (IBS)
Patients must provide medical history, records of failed treatments, and meet eligibility criteria.
—
TYPES OF MEDICAL CANNABIS PRODUCTS
LICENSED PRODUCTS
These are approved for specific uses:
Epidyolex: CBD oil for epilepsy.
Sativex: Oral spray with THC + CBD for MS spasticity.
Nabilone: Synthetic cannabinoid for nausea from chemotherapy.
UNLICENSED PRODUCTS
Prescribed mostly in private care, these include:
Cannabis flower (dried): Inhaled via vaporisers; fast onset.
Cannabis oil (oral): Slower acting, longer-lasting relief.
Capsules and tinctures
Vape cartridges (in some private settings)
In 2025, increasing volumes of UK-grown cannabis are now used in prescriptions, reducing reliance on imports.
—
HOW TO ACCESS MEDICAL CANNABIS
NHS ROUTE (RARE BUT POSSIBLE)
1. GP referral to a specialist.
2. Specialist assessment and decision.
3. Application for Individual Funding Request (IFR) if needed.
4. Treatment starts, possibly in a hospital setting.
Due to limited NHS guidelines and clinician reluctance, only a small fraction of prescriptions are issued via the NHS—less than 5% in 2025.
PRIVATE CLINIC PATHWAY
1. Online application and consultation booking.
2. Initial assessment (£49–£250).
3. Review of medical records (confirming failed treatments).
4. Prescription issued (monthly medication cost: £75–£500+).
5. Follow-up reviews every 3–6 months.
Patients can choose to collect medicines from pharmacies or have them delivered.
—
COSTS FOR PATIENTS
PRIVATE SECTOR COST BREAKDOWN (2025 AVERAGES)
Initial consultation: £50–£150
Monthly medication:
Cannabis flower: £50–£150 (10g)
Oils: £75–£250
Vape cartridges: £80–£120 (0.5ml)
SUPPORT PROGRAMS
Some clinics offer discounts through schemes like:
Project Twenty21: Reduced-cost treatment for those submitting outcome data.
Sapphire Access Scheme
Sapphire Foundation: Occasional grants for financially disadvantaged patients.
—
BENEFITS FOR PATIENTS
EFFECTIVE FOR TREATMENT-RESISTANT CONDITIONS
Studies and patient reports in 2025 highlight improvements in:
Seizure frequency in epilepsy
Muscle stiffness in MS
Chronic pain relief when opioids have failed
Sleep quality and reduced insomnia
Anxiety and PTSD symptoms
REDUCED RELIANCE ON OPIOIDS AND SLEEPING PILLS
Medical cannabis has allowed many patients to reduce or eliminate the need for:
Opioids
Benzodiazepines
Antidepressants
Sleeping tablets
This has led to improved quality of life and fewer side effects.
—
BARRIERS TO ACCESS
LIMITED NHS PARTICIPATION
Despite legalisation:
Only a handful of NHS prescriptions have been issued since 2018.
Clinicians remain risk-averse due to limited long-term trial data.
NICE guidelines are narrow in scope and based on high evidence thresholds.
LACK OF DOCTOR TRAINING
Most UK medical schools and hospitals provide little to no training on cannabis medicine. Many doctors feel uncomfortable discussing or prescribing CBMPs.
HIGH COST FOR PRIVATE CARE
Patients without financial means struggle to afford private treatment. Access remains unequal, particularly among low-income and elderly populations.
SUPPLY CHALLENGES
While domestic production has increased in 2025:
Import delays and prescription fulfillment issues remain.
Some patients report waiting 2–4 weeks for product delivery.
Product availability can be inconsistent depending on supplier.
—
UK GROWERS AND SUPPLY CHAIN (2025)
DOMESTIC PRODUCTION GROWTH
In 2024–25, major UK-based producers launched operations:
Glass Pharms: First licensed MHRA-grade UK cannabis grower.
Medical Cannabis Supporting Patients in the UK
Waterside Pharmaceuticals (BrewDog-backed): Industrial-scale indoor grower in Scotland.
Domestic cultivation is expected to reduce patient costs and ensure consistent product availability.
—
PATIENT EXPERIENCES AND TESTIMONIALS
CASE STUDY: PEDIATRIC EPILEPSY
Children like Alfie Dingley, whose mother Hannah Deacon led the charge to legalise cannabis, continue to benefit from CBMPs. Seizures have dropped from dozens per day to fewer than five per month in many cases.
Medical Cannabis Supporting Patients in the UK
CASE STUDY: VETERANS WITH PTSD
UK veterans using private clinics report significant reduction in:
Nightmares
Anxiety
Insomnia
Hypervigilance
SURVEY RESULTS (2025)
87% of patients report improved quality of life.
72% reduced or stopped at least one pharmaceutical medication.
82% said they preferred cannabis to opioids for pain relief.
—
FUTURE OUTLOOK
POLICY CHANGES ON THE HORIZON
Pressure is mounting on the NHS and NICE to:
Expand prescribing guidelines.
Accept real-world evidence alongside traditional clinical trials.
Train clinicians through official NHS pathways.
INCREASED RESEARCH FUNDING
In 2025:
More UK universities are undertaking medical cannabis trials.
NHS England’s Cannabis Prescription Registry is tracking outcomes to support future policy.
POTENTIAL FOR DECRIMINALISATION?
While full legalisation remains politically divisive, some MPs and patient groups are calling for:
Decriminalising possession for patients.
Creating a patient ID system to prevent wrongful arrests.
Better protection for legal cannabis users in employment and housing.
Medical Cannabis Supporting Patients in the UK
